Chemistry: molecular biology and microbiology – Measuring or testing process involving enzymes or... – Involving antigen-antibody binding – specific binding protein...
Reexamination Certificate
2006-09-19
2006-09-19
Winkler, Ulrike (Department: 1648)
Chemistry: molecular biology and microbiology
Measuring or testing process involving enzymes or...
Involving antigen-antibody binding, specific binding protein...
C435S005000, C435S069700, C436S501000
Reexamination Certificate
active
07108988
ABSTRACT:
The present invention provides screening methods for identifying a compound that induces loss of the lentiviral protein Vpr; screening methods for identifying compounds that inhibit the peptidyl-prolyl cis/trans isomerase (PPIase) activity of a protein that catalyzes cis-trans isomerization of cis-peptidylprolyl bonds in Vpr; and compounds identified by the screening methods. The compounds are useful for treating a lentiviral infection. The present invention further provides methods of inducing loss of the lentiviral protein Vpr; methods of inhibiting lentivirus viral replication; and methods of treating a lentivirus infection in an individual. The methods generally involve administering to an individual infected with the lentivirus an effective amount of a compound that induces Vpr loss and/or that inhibits PPIase activity of a protein that catalyzes cis-trans isomerization of cis-peptidylprolyl bonds in Vpr.
REFERENCES:
patent: 4814323 (1989-03-01), Andrieu et al.
patent: 5604092 (1997-02-01), Erlanger et al.
patent: 5612018 (1997-03-01), Bonyhadi et al.
patent: 5639598 (1997-06-01), Weiner et al.
patent: 5767069 (1998-06-01), Ko et al.
patent: 5773225 (1998-06-01), Luban et al.
patent: 5801144 (1998-09-01), Karpas et al.
patent: 5840305 (1998-11-01), Bukrinsky et al.
patent: 5948884 (1999-09-01), Luchinger
patent: 5976786 (1999-11-01), Finkel et al.
patent: 6030825 (2000-02-01), Hillman et al.
patent: 6177253 (2001-01-01), Erlanger et al.
patent: 6270957 (2001-08-01), Rich et al.
patent: 6700196 (1997-02-01), None
patent: 2226880 (1997-02-01), None
patent: 1192750 (1998-09-01), None
patent: 9800051 (1998-04-01), None
patent: 0842191 (2001-11-01), None
patent: 2000502320 (2000-02-01), None
patent: 315324 (1999-10-01), None
patent: WO 96/25175 (1996-08-01), None
patent: WO 97/04005 (1997-02-01), None
patent: WO 97/33604 (1997-09-01), None
patent: WO 99/10373 (1998-08-01), None
patent: WO 00/15208 (2000-03-01), None
Muthumani et al. Vpr-GFP virion particle identifies HIV-infected targets and preserves HIV-1 Vpr function in macrophages and T-cells. DNA and Cell Biology (2000) vol. 19, No. 3, pp. 179-188.
Stauber et al. Direct visualization of HIV-1 entry: Mechanism and role of cell surface receptors. Biochemical Biophysical Research Communications (1999) vol. 258, pp. 695-702.
Wu et al. Targeting foreign proteins to human immunodeficiency virus particles via fusion with Vpr and Vpx. Journal of Virology (1995) vol. 69, pp. 3389-3398.
Saphire et al. Trans-complementation rescue of cyclophilin A deficient viruses reveals that the recruitment for cyclophilin A in human immunodeficiency virus type 1 replication is independent of isomerase activity. Journal of Virology (Mar. 2002) vol. 76.
Sherman, et al., Nucleocytoplasmic Shuttling by Human Immunodeficiency Virus Type 1 Vpr. , Journal of Virology, Feb. 2001, vol. 75, No. 3, pp. 1522-1532.
Liu et al., Peptidyl-prolyl cis-trans-isomerase fromEscheria coli: Periplasmic Homolog of Cyclophilin that is not inhibited by Cyclosporine A. Proceedings of the National Academy of Science, Jun. 1990, vol. 87, No. 11, pp. 4028-4032.
Zhao, et al.Cyclophilin A Complexed with a Fragment of HIV-1 Gag Protein: Insights into HIV-1 Infectious Activity. Structure. Jan. 1997, vol. 5, No. 1, pp. 139-146.
Braaten, et al. “Cyclophilin A regulates HIV-1 infectivity, as demonstrated by gene targeting in human T cells”,The EMBO Journal(2001) vol. 20(6): 1300-1309.
Carpentier, et al. “Delineation of the calcineurin-interacting region of cyclophilin B”,Protein Science, (2000) vol. 9: 2836-2393.
Cohen, et al. “Human immunodeficiency virusvprproduct is a virion-associated regulatory protein”,J. Virology, (1990) vol. 64(6): 3097-3099.
He, et al. “Human immunodeficiency virus type 1 viral protein R (vpr) arrests cells in the G2phase of the cell cycle by inhibiting p34cdc2activity”,J. Virology,(1995) vol. 69(11): 6705-6711.
Heinsinger, et al. “The vpr protein of human immunodeficiency virus type 1 influences nuclear localization of viral nucleic acids in nondividing host cells”,Proc. Natl. Acad. Sci. USA,(1994) vol. 91; 7311-7315.
Kondo, et al. “A conserved LXXLF sequence is the major determinant in p6gagrequired for the incorporation of human immunodeficiency virus type 1 vpr”,J. Virology,(1996) vol. 70(1): 159-164.
Mlynar, et al. “The non-immunosuppressive cyclosporin A analogue SDZ NIM 811 inhibits cyclophilin A incorporation into virions and virus replication in human immunodeficiency virus type 1-infected primary and growth-arrested T cells”,J. General Virology,(1997) vol. 78: 825-835.
Rizzardi, et al. “Treatment of primary HIV-1 infection with cyclosporin A coupled with highly active antiretroviral therapy”,J. Clin. Investigation,(2002) vol. 109(5): 681-688.
Bruns Karsten
Greene Warner
Henklein Peter
Schubert Ulrich
Sherman Michael
Borden Paula A.
Bozicevic Field & Francis LLP
The J. David Gladstone Institutes
Winkler Ulrike
LandOfFree
Methods of identifying agents for inhibiting lentivirus... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods of identifying agents for inhibiting lentivirus..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods of identifying agents for inhibiting lentivirus... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3537639